Gretchen Kimmick

机构：Duke University, Duke Medical Center · ORCID：0000-0001-7096-9624

发表论文 264 篇 · 总被引 7924 次 · h-index 47

代表论文

• TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. (2024 · Journal of Clinical Oncology · 被引 20)
• Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting (2024 · Breast Cancer Research · 被引 13)
• First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting (2024 · Breast Cancer Research and Treatment · 被引 8)
• Association of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer (2023 · Supportive Care in Cancer · 被引 6)
• The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2− Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered (2025 · Clinical Drug Investigation · 被引 5)
• Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011–2022 (2025 · Breast Cancer Research and Treatment · 被引 5)